Phenotype Screening Corporation (United States)
- Research works
- 1 ▼ 48% vs 2013–17
- Citations
- 23 19.2 per fractional work
- Top-10% rate
- 0.0% record average 16.5%
- Open access
- 41% world 28%
Not ranked overall: Phenotype Screening Corporation (United States) is under the volume floor below which an excellence rate is noise. Not ranked is not the same as ranked last.
Which research topics does Phenotype Screening Corporation (United States) publish most on?
By volume in 2022–2025: Peptidase Inhibition and Analysis, Cancer Immunotherapy and Biomarkers and Radiopharmaceutical Chemistry and Applications.
Area is fractional works; colour is the subfield each topic belongs to.
- 1 Peptidase Inhibition and Analysis Oncology 0 works
- 2 Cancer Immunotherapy and Biomarkers Oncology 0 works
- 3 Radiopharmaceutical Chemistry and Applications Radiology, Nuclear Medicine and Imaging 0 works
How open and international is its research?
Against the world’s own shares — the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.
World: 28% of research is openly available.
World: 19% is written across borders.
How has Phenotype Screening Corporation (United States)'s research output changed?
Output in 2018–2022 was 48% lower than in 2013–2017.
Other research institutions in Knoxville
- University of Tennessee at Knoxville
- Johnson University
- Knoxville College
- Tennessee Valley Authority
- University of Tennessee Medical Center
- South College
- University Radiology
- National Transportation Research Center
Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners are in the interactive view on the map.